Pregnancy in adult‐onset dermatomyositis/polymyositis: A systematic review. (23rd August 2022)

• Record Type: Journal Article
• Authors: Tang, Keyun; Zhou, Jia; Lan, Yining; Zhang, Hanlin; Jin, Hongzhong
• Is Part Of: American journal of reproductive immunology. Volume 88:Number 5(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-08-23
• Subjects: dermatomyositis -- myositis -- polymyositis -- pregnancy outcomes -- treatment; Human reproduction -- Immunological aspects -- Periodicals; 616.69206
• DOI: 10.1111/aji.13603
• Languages: English
• ISSNs: 1046-7408

Abstract

Abstract: Background: Idiopathic inflammatory myopathy (IIM) in pregnancy is uncommon but may result in complications for both mother and the fetus. Aim: In this systematic review, we summarized the current literature investigating outcomes of pregnancy related to the dermatomyositis/polymyositis (DM/PM) process. Content: We searched PubMed, Embase, Cochrane Library, and Web of Science databases and included 61 studies reporting the disease course, pregnancy outcomes, and management of both pregnancy and DM/PM in the final analysis.The specific information of 221 pregnancies was extracted and these pregnancies were divided into three distinct forms: pregnancies after disease onset ( n = 159), pregnancies with new disease onset ( n = 37), and pregnancies followed by postpartum onset ( n = 25). In most cases, DM/PM disease activity remained stable or improved throughout pregnancy (80.2%) and the postpartum period (83.9%). Active DM/PM during pregnancy significantly increased the risk of stillbirth or neonatal death (12% vs. 1%, P = .005) and preterm birth (34.7% vs. 11%, P < .001). The rates of other poor outcomes (total fetal loss, low birth weight, and intrauterine growth retardation) were also increased in pregnancies with active disease. Mainstay treatments for active DM/PM during pregnancy are glucocorticoids and intravenous immunoglobins. Implications: The present results underline the importance of good control of myopathy in optimizing the pregnancy outcomes of women with DM/PM.